On the one hand, a high level of innovation in the biopharma sector heralds a new era of therapeutic breakthroughs, but on the other hand the industry is wracked by the debate over how society will pay for its treatments. Even while approvals for cell and gene therapies were cause for much jubilation last year and therapeutic R&D is thriving, uncertainty around the perceived threat of drug price reform measures in the US dragged biotech stock prices down in the latter part of 2018: between the beginning of September and Christmas, The S&P XBI biotech stock index lost more than a third of its value.
This tension between R&D progress and commercial opportunity was reflected in the comments of many of the 40+ industry experts asked by Scrip
This is the third and final installment in our Scrip Asks...What Does 2019 Hold For Biopharma? series
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?